This effect is analogous to that of other anti-cancer drugs, including the natural occurring polyphenol Resveratrol, various HDACi (e.g. SAHA, Romidepsin, Trichostatin A, Valproate), and proteasome inhibitors (e.g. Bortezomib), that were shown to upregulate MICA/B (detected with an antibody recognizing both MICA and MICB molecules) and ULBP2 in Jurkat or MOLT-4 cells56–60. Here, MICA is linked to cancer.